Safe and Appropriate Use of GLP-1 RAs in Treating Adult Patients With Type 2 Diabetes and Macrovascular Disease.

Citation metadata

Date: Sept. 2022
From: Journal of Family Practice(Vol. 71, Issue 7)
Publisher: Jobson Medical Information LLC
Document Type: Report; Author abstract
Length: 426 words
Lexile Measure: 1360L

Document controls

Main content

Article Preview :

Macrovascular complications, particularly cardiovascular disease (CVD), are the greatest contributors to the morbidity, mortality, and cost of diabetes mellitus. Atherosclerotic cardiovascular disease (ASCVD) is the most important macrovascular complication, and type 2 diabetes (T2D) and its associated hyperglycemia are major risk factors for ASCVD.

Some antihyperglycemic therapies for T2D, including some sodium-glucose cotransporter-2 inhibitors, thiazolidinediones, and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated benefit in CVD and chronic kidney disease (CKD).

GLP-1, a potent incretin hormone, enhances insulin and inhibits glucagon secretion in a glucose-dependent manner; it also inhibits gastric emptying and gastric acid secretion and increases satiety. GLP-1 RAs mimic endogenous GLP-1 but have...

Source Citation

Source Citation   

Gale Document Number: GALE|A722030331